Global Orphan Drugs Market

Precision medicine refers to a type of medication that prevents, detects, or treats disease using knowledge about a person's own genes or proteins. In order to choose a treatment that may be most effective for a person, precision medicine considers their genetics, environment, and lifestyle. The main technologies involved in precision medicine are bioinformatics, big data analytics, drug discovery, gene sequencing, companion diagnostics, and others. Bioinformatics technologies involve the application of computational tools to organize, analyze, understand, visualize and store information associated with biological macromolecules. It is used in oncology, respiratory diseases, central nervous disorders, immunology, genetic diseases, others and is implemented in various sectors such as hospitals and clinics, pharmaceuticals, diagnostic companies, healthcare, and IT firms, among others. The precision medicine market research report is one of a series of new reports from The Business Research Company that provides precision medicine market statistics, including precision medicine industry global market size, regional shares, competitors with a precision medicine market share, detailed precision medicine market segments, market trends and opportunities, and any further data you may need to thrive in the precision medicine industry. This precision medicine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global precision medicine market size grew from $83.43 billion in 2022 to $95 billion in 2023 at a compound annual growth rate (CAGR) of 13.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The precision medicine market size is expected to grow to $157.26 billion in 2027 at a CAGR of 13.4%. The rising prevalence of cancer is projected to fuel the growth of the precision medicine market in the coming years. Cancer is one of the main causes of death worldwide, with one out of every five individuals developing cancer at some point in their lives. Precision medicine in cancer entails analyzing DNA from tumors to find mutations or other genetic abnormalities that cause cancer. Physicians may therefore be able to choose a treatment for a specific patient's cancer that best fits, or targets, the tumor DNA alterations. For instance, according to recent predictions from the International Agency for Research on Cancer (IARC), the global cancer burden increased to 19.3 million cases and 10 million cancer deaths in 2020. Therefore, the rising prevalence of cancer drives the growth of the precision medicine market. The development of novel precision medicine for pancreatic cancer is shaping the precision medicine market. Extensive research is being undertaken on different approaches to develop precision medicines for pancreatic cancer. For instance, in October 2020, Scientists from the University of Glasgow announced the development of a novel precision medicine approach for treating the damaged DNA in the cancer cells of pancreatic cancer patients. The team used grown cells from the lab, and replicas of patients' tumors, to find molecular markers, which were used in the prediction and response to several drugs, targeting DNA damage. The researchers tested certain markers using multiple drugs, also developed a strategy that is taken forward into a clinical trial. The trial will help doctors and researchers to predict which patient will respond to one of these drugs, either alone or in combination. In April 2021, Servier Laboratories, a France-based pharmaceutical company acquired Agios Pharmaceuticals Inc.,’s commercial, clinical, and research-stage oncology portfolio for an undisclosed amount. The acquisition of Servier Laboratories is focused on strengthening its commercial presence in the malignant technology market and provides the potential for long-term growth into the solid tumor space. The transaction includes marketed oncology precision medicine in malignant technology, clinical oncology pipeline with multiple early-stage and phase-3 assets. Agios Pharmaceuticals is a US-based company focused on developing small-molecule anti-cancer therapeutics targeting cancer cell metabolism via the growth factor pathway. Major players in the precision medicine market are Qiagen, Novartis AG, Medtronic, AstraZeneca plc., Quest Diagnostics, Thermo Fisher Scientific Inc., Pfizer, Bristol-Myers Squibb, Merck & Co. Inc., Tepnel Pharma Services, Abbott Laboratories, Takeda Pharmaceutical Company Ltd., and Eli Lilly and Company. North America was the largest region in the precision medicine market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the precision medicine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the precision medicine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The precision medicine market consists of sales of imatinib, personalized medicine, and individualized medicine. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global precision medicine market is segmented - 1) By Technology: Big Data Analytics, Bioinformatics, Gene Sequencing, Drug Discovery, Companion Diagnostics, Other Technologies 2) By Application: Oncology, Respiratory Diseases, Central Nervous System Disorders, Immunology, Genetic Diseases, Other Applications 3) By End-User: Hospitals And Clinics, Pharmaceuticals, Diagnostic Companies, Healthcare And IT Firms, Other End-Users

Pharmaceutical drug refers to a substance created to treat, prevent, or cure an illness or other condition, or to lessen its symptoms. To list the most popular methods, drugs can be consumed orally, through a skin patch, by injection, or through an inhaler. Other vital medications made from natural materials include vaccinations, steroid hormones, human blood-plasma fractions, and antibiotics. The main types of pharmaceutical drugs are cardiovascular drugs, dermatology drugs, gastrointestinal drugs, genito-urinary drugs, hematology drugs, anti-infective drugs, metabolic disorders drugs, musculoskeletal disorders drugs, central nervous system drugs, oncology drugs, ophthalmology drugs, and respiratory diseases drugs. Cardiovascular drugs are used to treat medical conditions associated with the heart or the circulatory system (blood vessels), such as arrhythmias, blood clots, coronary artery disease, high or low blood pressure, high cholesterol, heart failure, and stroke. The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores, and others. The pharmaceutical drug market research report is one of a series of new reports from The Business Research Company that provides pharmaceutical drug market statistics, including pharmaceutical drug industry global market size, regional shares, competitors with a pharmaceutical drug market share, detailed pharmaceutical drug market segments, market trends and opportunities, and any further data you may need to thrive in the pharmaceutical drug industry. This pharmaceutical drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global pharmaceutical drugs market is expected to grow from $ 1,136.23 billion in 2022 to $1,199.86 billion in 2023 at a compound annual growth rate (CAGR) of 5.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, affecting many markets across the globe. The pharmaceutical drugs market is expected to reach $1,848.49 billion in 2027 at a CAGR of 11.4%. The rise in sedentary jobs, busy lifestyles, and changing consumer preferences are affecting the disease profile of the world population, especially non-communicable diseases such as cancer, diabetes, and cardiovascular diseases. Long working hours, less physical activity, and unhealthy eating and drinking habits are major causes of chronic diseases such as diabetes. According to the World Health Organization, chronic disease prevalence rose by 57% globally, in the year 2020. China and India together had about 193.4 million diabetic patients in 2019 and India is expected to have about 101 million diabetic patients by 2030, thereby increasing the need for biologics drugs for diabetic patients. These factors are expected to increase the patient pool globally, thereby driving the pharmaceutical drug market during the forecast period. Interest rates globally are forecasted to rise in most of the developing and developed economies, during the forecast period, this is expected to limit new investments in the market. Most countries across the world are raising interest rates to control inflation and also to limit the flow of capital out of the country. This is likely to affect new investments in terms of expansion, research, and development of new products. For instance, the US interest rates rose to 3.5% by 2021. These factors are expected to hurt the market as borrowing money becomes expensive, thereby affecting the pharmaceuticals market growth. Early Rx-to-OTC switch, or switching the product from prescription to non-prescription status, is a key trend in the dermatology drugs market. Traditionally, the Rx-to-OTC status conversion was generally observed at a phase nearing the patent expiry or after. However, forward-thinking companies are now looking at switching from Rx-to-OTC well in advance of the patent expiry of the drug. This helps the manufacturer to capitalize on the market opportunities for the product. Early Rx-to-OTC switching also provides an additional benefit as a way to recover all the expenses incurred on the product by the company. For example, in 2020, FDA has switched three prescription drugs to OTC including Voltaren for arthritis pain, olopatadine hydrochloride 0.1% and 0.2% (Pataday Twice Daily Relief and Pataday Once Daily Relief) for temporary relief of itchy and red eyes due to pollen, ragweed, and grass. Major companies in the pharmaceutical drugs market include Bristol-Myers Squibb, Sanofi S.A, Johnson & Johnson, Novartis AG, Bayer AG, Abbott Laboratories, GlaxosmithKline, AstraZenec, Merck & Co and CJ Corp. North America was the largest region in the pharmaceutical drugs market in 2022. Middle East is expected to be the fargest growing region in the forecast period. The regions covered in the pharmaceutical drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the pharmaceutical drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The pharmaceutical drug market consists of sales of generic drugs, over-the-counter medications, bulk drugs, vaccines, biosimilars, and biologics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global pharmaceutical drugs market is segmented - 1) By Type: Cardiovascular Drugs, Dermatology Drugs, Gastrointestinal Drugs, Genito-Urinary Drugs, Hematology Drugs, Anti-Infective Drugs, Metabolic Disorders Drugs, Musculoskeletal Disorders Drugs, Central Nervous System Drugs, Oncology Drugs, Ophthalmology Drugs, Respiratory Diseases Drugs 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Other Distribution Channels 3) By Route Of Administration: Oral, Parenteral, Other Route Of Administration 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode Of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs Subsegments Covered: Anti-Hypertensive Drugs, Hypolipidemics, Anti Thrombotics, Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrhythmic And Anti-Anginal Drugs), Acne Drugs, Dermatitis, Psoriasis, Other Drugs for Dermatology Diseases, Antacids, Antiulcerants, Vitamin And Minerals, Antiobesity, Antiemetics And Antinauseants, Antidiarrhoeals, Hormonal Contraceptives, Drugs For Benign Prostatic hypertrophy, Drugs For Infertility, Drugs For Erectile Dysfunction, Drugs For Urinary Incontinence And Overactive Bladder, Drugs For Infections And Others, Drugs For Hormonal Replacement Therapy, Diuretics, Blood Products, Anemia And Other Blood Disorder Drugs, Antibiotics, Antivirals, Antifungals, Others (Anthelminthic, Antiprotozoal), Anti Diabetics drugs, Anti-Thyroid Drugs, Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism), Drugs For Rheumatoid Arthritis, Muscle Relaxants, Other Musculoskeletal Disorders Drugs, Analgesics, Anti-Parkinson drugs, Anesthetics, Anti-Epileptics, Other CNS drugs, Lung Cancer Drugs, Pancreatic Cancer Drugs, Breast Cancer Drugs, Prostate Cancer Drugs, Ovarian Cancer Drugs, Colorectal Cancer Drugs, Gastric Cancer Drugs, Kidney Cancer Drugs, Brain Tumor Drugs, Thyroid Cancer Drugs, Skin Cancer Drugs, Bladder Cancer Drugs, Cervical Cancer Drugs, Blood Cancer Drugs, Others (Kaposi Sarcoma, AIDS-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma), Antiglaucoma Drugs, Dry Eye Medication, Other Ophthalmological Drugs (Retinal Disorders, Anti-Infectives/Allergy), Anti-Asthmatics And COPD Drugs, Cough And Cold Preparations

Orthrobiologic devices are implants composed of cells and proteins that are naturally found in the human body and that provide accelerated healing by stimulating efficient regrowth of musculoskeletal tissues, including bones, cartilage, tendons, and ligaments. The main product types of orthobiologics devices and equipment are demineralized bone matrix, synthetic bone substitutes, stem cell therapy, plasma-rich protein, viscosupplementation, bone morphogenetic protein, and synthetic orthobiologics. Stem cell therapy is promoting the repair response of diseased, dysfunctional, or injured tissue using stem cells or their derivatives. The various applications involved are osteoarthritis and degenerative arthritis, soft-tissue injuries, fracture recovery, maxillofacial and dental applications, spinal fusion, trauma repair, and reconstructive surgery that are used by various end-users such as hospitals, orthopedic clinics, and others. The orthobiologics devices and equipment market research report is one of a series of new reports from The Business Research Company that provides orthobiologics devices and equipment market statistics, including orthobiologics devices and equipment industry global market size, regional shares, competitors with a orthobiologics devices and equipment market share, detailed orthobiologics devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the orthobiologics devices and equipment industry. This orthobiologics devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global othobiologics devices and equipment market grew from $4.86 billion in 2022 to $5.29 billion in 2023 at a compound annual growth rate (CAGR) of 8.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The othobiologics devices and equipment market is expected to grow from $6.85 billion in 2027 at a CAGR of 6.7%. The aging population profile of most countries contributed to the growth of orthobiologics devices and equipment market globally. According to the United Nations report, there were 962 million people aged over 60 across the globe, comprising 13% of the global population. The population aged over 60 is expected to grow at a rate of about 3% every year. The report further estimated that Europe had the highest percentage of the population aged over 60. The number of people globally over the age of 65 grew by 33%, according to estimates based on Population Reference Bureau data. The increase in the aging population has increased the patient pool of many orthopedic disorders and led to an increase in the demand for orthobiologics devices and equipment market. Rising incidences of post-surgical complications in patients implanted with orthobiologics devices are one of the major restraints in the orthobiologics devices and equipment market. Surgical procedures with orthobiologics grafts, implants, and devices have become increasingly common in recent years. Major postoperative complications include device failures, bleeding, postoperative infections, immune responses, and rejections. These procedures may develop post-surgery complications which refer to the development of any unwanted or unexpected conditions related to the device, graft, or implant. These complications may vary with the type of procedure, implant, graft, or device, the experience of the surgeon, improper device testing procedures before market launch, device location in the body, and the health and biological response of the individual. The increasing post-operative complications and device failures can limit the orthobiologics devices and equipment market. Biodegradable implants are increasingly being used in orthobiologics treatment and trauma orthopedic surgeries. Biodegradable implants are used to replace a missing biological structure, support a damaged biological structure, and enhance the existing bone structure. Biodegradable products such as re-absorbable polymers composed of polyglycolic acid and polylactic acid manufactured in the form of plates, screws, and pins are replacing traditional devices like plates and screws which are more expensive. Surgeons are preferring biodegradable implants to replace conventional implants, as biodegradable implants can be engineered to provide temporary support for bone fractures, can degrade at a rate matching new tissue formation, eliminate the need for the second surgery, and are highly useful in fracture fixation in children with less implant-related infections. For instance, Stryker Corp. offers orthobiologics such as bone repair biodegradable products that are used in bone regeneration and bone healing, soft tissue regeneration, and muscle connection to bone Regulatory changes are likely to lead to increased costs relating to new product development and supply of orthobiologics devices. These changes are related to customer data protection such as the European Union's General Data Protection Regulation (GDPR), changes to equipment approval procedures, and other regulatory changes. The GDPR is an EU law on the data protection and privacy of individuals residing in the European Union and the European Economic Area (EEA). It also regulates the export of personal data outside the EU and EEA areas. Additionally, the FDA is requesting more clinical data to support claims, therefore increasing the time to process 510(k)s by over 55% over the last decade. In November 2017, the USFDA has announced a comprehensive regenerative medicine policy framework to facilitate innovation. This policy deals with the manufacture of tissues, human cells, and cellular and tissue-based products other procedures to prevent the introduction, transmission, and spread of communicable diseases. Orthobiologics such as stem cell therapies are approved through this framework. The potential loss of revenue due to delays in product release, additional costs incurred by the time-consuming approval processes, and changing regulations puts a strain on investments relating to orthobiologics devices development. Major players in the orthobiologics devices and equipment market are Medtronic, Arthrex Inc., DePuy Synthes (A Subsidiary of Johnson & Johnson), Stryker Corporation, Zimmer Biomet, Bioventus LLC., Baxter International Inc., Integra Lifesciences Holding Corporation, Nuvasive Inc., and Sanofi. North America was the largest region in the global orthobiologics devices and equipment market in 2022. Western Europe was the second-largest region in the orthobiologics devices and equipment market. The regions covered in global orthobiologics devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The counties covered in the orthobiologics devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, and Australia. The orthrobiologic devices market consists of sales of demineralized bone matrix, synthetic bone substitutes, stem cell therapy, plasma-rich protein, viscosupplementation, bone morphogenetic protein, and other synthetic orthobiologics. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global orthobiologics devices and equipment market is segmented - 1) By Product Type: Demineralized Bone Matrix, Synthetic Bone Substitutes, Stem Cell Therapy, Plasma-Rich Protein, Viscosupplementation, Bone Morphogenetic Protein, Synthetic Orthobiologics 2) By Application: Osteoarthritis and Degenerative Arthritis, Soft-Tissue Injuries, Fracture Recovery, Maxillofacial and Dental Applications, Spinal Fusion, Trauma Repair, Reconstructive Surgery 3) By End Use: Hospitals, Orthopedic Clinics, Other End Users

The erectile dysfunction (ED) drugs refer to the drugs that are used to improve the effects of nitric oxide, a substance your body naturally generates that relaxes penile muscles, to treat erectile dysfunction. Erectile dysfunction is the inability to achieve or keep up a penile erection in men. The different types of drugs in erectile dysfunction (ED) drugs are sildenafil citrate, mirodenafil, and vardenafil. Sildenafil is a drug that is used to treat erectile dysfunction and pulmonary arterial hypertension. It is offered under the trade names Viagra and others. It’s unknown whether it’s effective in treating female genital dysfunction. The different routes of administration include Oral, topical, and injections and are used by hospital pharmacies, retail pharmacies, and online pharmacies. The erectile dysfunction (ED) drugs market research report is one of a series of new reports from The Business Research Company that provides erectile dysfunction (ED) drugs market statistics, including erectile dysfunction (ED) drugs industry global market size, regional shares, competitors with erectile dysfunction (ED) drugs market share, detailed erectile dysfunction (ED) drugs market segments, market trends and opportunities, and any further data you may need to thrive in the erectile dysfunction (ED) drugs industry. This erectile dysfunction (ED) drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global drugs for erectile dysfunction market size will grow from $3.21 billion in 2022 to $3.25 billion in 2023 at a compound annual growth rate (CAGR) of 1.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global drugs for erectile dysfunction market size is expected to grow to $3.36 billion in 2027 at a CAGR of 0.8%. The drastic increase in the number of chronic diseases drives the erectile dysfunction drug market. Erectile dysfunction is mainly caused by chronic diseases resulting from a sedentary lifestyle such as cardiovascular diseases, diabetes, obesity, and high blood pressure. According to WHO, the prevalence of chronic diseases is expected to grow by 57% by the end of the year 2020. Prevalence of chronic diseases increases the chances of erectile dysfunction among men, thereby driving the erectile dysfunction drug market. Patients suffering from erectile dysfunction do not seek treatment owing to factors such as lack of education, lack of awareness, strong religious beliefs, social taboo, and low socioeconomic status. These factors are responsible for the patients suffering from erectile dysfunction rejecting or avoiding the treatment. For example, according to a survey conducted by Opinium Research in February 2020, just 27% out of the total 2,006 men surveyed were aware that erectile dysfunction could be linked to high blood pressure or elevated cholesterol while just 22% of men surveyed were aware that erectile dysfunction is often associated with diabetes. These factors restrain the growth of the erectile dysfunction drug market. New drug delivery techniques such as the use of pellets and creams are being implemented by many companies in the erectile dysfunction drugs market. Pellets and creams will have more efficacy and performance in erectile dysfunction and these are also more effective and safer to use. These benefits from drug delivery techniques will increase the scope of the erectile dysfunction drug market. For example, In September 2022, Lupin, an India-based pharmaceutical company launched Sildenafil for oral suspension, 10 mg/mL with the approval of the United States Food and Drug Administration (FDA). This drug is for erectile dysfunction with unique dosages. Medicines are authorized by regulatory bodies based on quality, safety, and efficacy to make sure that medicines are of standard quality and gives positive benefit. Companies are mandated to submit the documentation for the standard quality before applying for authorization. The safety and efficacy of medicines should be demonstrated by clinical trials for all new medicines by the companies. Competent authorities will assess this data before authorizing the drugs. In Europe, the European Medicines Agency (EMA) assesses the drugs for centrally authorized products. Major players in the erectile dysfunction (ED) drugs market are Eli Lilly and Co., Pfizer, Bayer AG, Dong-A Pharmaceutical Co. Ltd., Vivus, Meda Pharmaceuticals, Apricus Biosciences, Cristália, S.K. Chemicals Co and Teva Pharmaceutical Industries Ltd. North America was the largest region in the erectile dysfunction (ED) drugs market in 2022. Middle East is expected to be the fastest-growing region in the global drugs for erectile dysfunction market during the forecast period. The regions covered in the global erectile dysfunction (ED) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the erectile dysfunction (ED) drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The erectile dysfunction (ED) drugs market consists of sales Sildenafil (Viagra), vardenafil (Levitra, Staxyn), tadalafil (Cialis) and avanafil (Stendra). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global drugs for erectile dysfunction market is segmented - 1) By Drugs: Sildenafil Citrate, Mirodenafil, Vardenafil 2) By End users: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 3) By Mode of Administration: Oral, Topical, Injections

Anemia and Other Blood Disorder Drugs refer to the medications or drugs that are used to treat anemia and other blood disorder diseases. It refers to a blood condition that develops when a medication prompts the body's immune system to begin attacking its own red blood cells. Hemolysis, a process that causes red blood cells to degrade earlier than usual, is brought on by this. The main types of anemia and other blood disorder drugs are iron deficiency anemia, chronic kidney disease anemia, sickle cell anemia, and aplastic anemia. Iron deficiency anemia is a common kind of anemia in which the blood does not contain enough healthy red blood cells. The oxygen-carrying red blood cells transport oxygen to the body's cells. The different types of anemia include microcytic (Low MCV), normocytic (Normal MCV), and macrocytic (High MCV) and involve various routes of administration such as oral, and injectable. It is distributed through hospitals pharmacies, online pharmacies, and pharmacy. The anemia and other blood disorder drugs market research report are one of a series of new reports from The Business Research Company that provides anemia and other blood disorder drugs market statistics, including anemia and other blood disorder drugs industry global market size, regional shares, competitors with anemia and other blood disorder drugs market share, detailed anemia and other blood disorder drugs market segments, market trends and opportunities, and any further data you may need to thrive in the anemia and other blood disorder drugs industry. This anemia and other blood disorder drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global anemia and other blood disorder drugs market size will grow from $11.14 billion in 2022 to $11.87 billion in 2023 at a compound annual growth rate (CAGR) of 6.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global anemia and other blood disorder drugs market size is expected to grow to $14.80 billion in 2027 at a CAGR of 5.7%. The increasing prevalence of anemia among the global population acts as a strong driving factor for the market. Unhealthy lifestyles, changing dietary habits and increased stress levels increased the cases of anemia worldwide. For instance, anemia was found to be the most frequent disease in the elderly population (> 65 years of age), reaching a prevalence rate of around 17%. the World Bank reported that anemia is the 8th leading cause of disease among women and the young population. Growth in the prevalence rate of anemia drives the market. There has been an increase in the use of biologics for treating anemia and other blood disorders. Biologics are composed of protein, sugar, nucleic acids, or a combination of these substances or might be derived from living organisms like humans, animals, or microorganisms or that may contain components of living organisms. The growth in the use of biologics over the drugs restricts the market resulting in the decline of the number of drugs being used for the treatment of anemia& other blood disorders. For example, Hospira, a medical device and pharmaceutical company, submitted its first biologics license application to FDA for the approval of a drug that treats anemia. Moreover, the FDA approved the first Epoetin Alfa biosimilar for the treatment of anemia caused by chronic kidney disease, chemotherapy, or the use of zidovudine in patients with HIV infection. The increase in the use of biologics will hamper the growth of the market. Companies in the anemia and other blood disorder drugs market are collaborating with other companies to develop and commercialize a specific kind of drug by sharing the knowledge, technology, and cost. Such collaborations are also helpful to the companies in case of expiring licenses and a stringent regulatory environment. For example, in 2020, Akebia Therapeutics announced collaboration with Tobacco Inc. to treat adult patients with iron deficiency anemia. Another such example is, Akebia Therapeutics Inc. and Otsuka Pharmaceutical Co. Ltd. agreed to manufacture and commercialize vadadustat, an oral HIF stabilizer, used for the treatment of anemia. The anemia and other blood disorder drugs market is governed by several regulatory bodies that regulate their functioning by carrying out quality checks for that drug before it can be launched in the market. For instance, the U.S. Food & Drug Administration (FDA) requires every pharmaceutical company to get its drugs examined by the concerned authority. FDA sorts to a Risk Evaluation and Mitigation Strategy (REMS) for determining the safety and quality standards of the drug and grants approvals only if the standards are up to the mark. In October 2022, Pfizer, a US-based pharmaceutical company acquired Global Blood Therapeutics Inc. for an undisclosed amount. Through this acquisition, Pfizer expanded its portfolio in the development of drugs and brought various potential best-in-class treatments to people living with sickle cell disease. Global Blood Therapeutics Inc. is a US-based biotech company operating in anemia and other blood disorder drugs. Major players in the anemia and other blood disorder drugs market are Amgen Inc., GlaxoSmithKline PLC., Akebia Therapeutics, Bayer AG, Pfizer Inc., Regenbiopharma, Hoffmann-La Roche Ltd., Merck Sharp &Dohme Corp., Novartis AG and Janssen Pharmaceutical. North America was the largest region in the anemia and other blood disorder drugs market in 2022. Middle East is expected to be the fastest-growing region in the global anemia and other blood disorder drugs market during the forecast period. The regions covered in the global anemia and other blood disorder drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the anemia and other blood disorder drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The anemia and other blood disorder drugs market consists of sales of folate analogues, multivitamin and mineral supplements, iron supplements, and erythropoiesis-stimulating agents. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global anemia and other blood disorder drugs market is segmented - 1) By Type: Iron Deficiency Anemia, Chronic Kidney Disease Anemia, Sickle Cell Anemia, Aplastic Anemia 2) By Distribution Channel: Hospitals Pharmacy, Online Pharmacy, Pharmacy 3) By Route of Administration: Oral, Injectable 4) By Anemia Type: Microcytic (Low MCV), Normocytic (Normal MCV), Macrocytic (High MCV)

Lung cancer drugs refer to anti-angiogenic drugs that are used to treat lung cancer. Lung cancer is a type of cancer that decreases the ability of the lungs to supply oxygen to the bloodstream because of the uncontrolled growth of tissues in the lung. Some of the possible treatments for lung cancer include surgery, chemotherapy, radiation therapy, and targeted therapy. Based on the size of the tumor cells, lung cancer is broadly divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). The main types of diseases in lung cancer drugs are small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Small cell lung cancer is a type of lung cancer that grows quickly in the lungs' tissues. Small cell lung cancer has often expanded (metastasized) outside of the lungs by the time a person receives a diagnosis. This malignancy is also more likely to recur after therapy than other types of lung cancer. The different types of drugs include Gemzar, paraplatin, Taxotere, navelbine, avastin, Tarceva, Iressa, and others and are used in various sectors such as hospitals, clinics, and others. The lung cancer drugs market research report is one of a series of new reports from The Business Research Company that provides lung cancer drugs market statistics, including lung cancer drugs industry global market size, regional shares, competitors with a lung cancer drugs market share, detailed lung cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the lung cancer drugs industry. This lung cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global lung cancer drugs market size will grow from $32.67 billion in 2022 to $36.53 billion in 2023 at a compound annual growth rate (CAGR) of 11.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global lung cancer drugs market size is expected to grow to $54.43 billion in 2027 at a CAGR of 10.5%. The rising prevalence rate of lung cancer is a major driver for the lung cancer market. This is mainly because an increase in the prevalence and incidence rate of lung cancer cases propels the need for drugs that enable efficient and fast treatment of the disease. It also drives the industry to maintain a strong pipeline of drugs. According to the World Health Organization report, cancer led to around 10 million deaths in 2020, out of which, lung cancer was responsible for the largest number of deaths (1.80 million deaths). The increasing use of biologics and targeted therapies is a major restraint for the lung cancer market. This is because chemical lung cancer drugs come with myriads of side effects and have a toxic effect on the body. Chemical drugs lack cell specificity, i.e., they destroy even the normal body cells along with cancer-infected cells. While biologic drugs are highly targeted and work on cancer-infected cells only. Biologic drugs are also very efficient with no side effects. Clinical studies have also found that the probability of success of biological drugs is much higher than that of conventional chemical drugs. For example, Cetuximab, Gefitinib, and Afatinib are lung cancer biologic drugs that specifically target only the muted form of tumours and do not destroy the normal body cells. Targeted drug therapy in combination with other therapies is an emerging trend in the lung cancer market. It involves the use of immunotherapy drugs combined with other therapies such as chemotherapy that help in early diagnosis, prevention, and treatment of the disease. In this regard, drug manufacturers are developing targeted drug therapies for better diagnosis and treatment of lung cancer. For example, Merck and Co. developed pembrolizumab, which is a drug that helps the immune system to detect and fight cancer cells when used in addition to chemotherapy. This combination therapy showed an improvement in lung cancer status in patients. The drug is a major product of Merck and Co. and is sold under the brand name Keytruda. The FDA's guidelines for lung cancer drugs are mentioned within the Code for Federal Regulations (CFR) title number 21 under part 312, which contains sub-parts from 'A' to 'I'. The sub-part 'E' deals with the procedures designed to push the development, evaluation, and marketing of drugs related to therapies aimed to treat persons with life-threatening illnesses such as lung cancer. The subpart 'E' also includes guidelines for monitoring and evaluation of clinical trials of lung cancer drugs and other cancer drugs by agency officials to determine whether new treatments are safe and effective, or better than existing treatments. All drug manufacturers are required to abide by these regulations by the FDA. Hence, regulations such as these would also keep a check on manufacturers of lung cancer drugs. Major players in the lung cancer market are Bristol-Myers Squibb Company, Merck & Co., F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., GlaxoSmithKlin, Vertiv Co., Sanofi-Aventis, Sun Pharmaceuticals Industries and Celgene Corporation. North America was the largest region in the lung cancer drugs market in 2022. Middle East is expected to be the fastest-growing region in the global lung cancer drugs market during the forecast period. The regions covered in the lung cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the lung cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The lung cancer drugs market consists of sales of bevacizumab, atezolizumab, and ramucirumab. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global lung cancer drugs market is segmented - 1) By Disease Type: Small cell lung cancer (SCLC), Non-small cell lung cancer (NSCLC) 2) By End User: Hospitals, Clinics, Other End-Users 3) By Drugs: Gemzar, Paraplatin, Taxotere, Navelbine, Avastin, Tarceva, Iressa, Other Drugs

Brain and neuroimaging devices are medical devices used to capture the structure, function, or pharmacology of the brain and locate areas affected by neurological disorders. The main imaging types of brain and neuroimaging devices are functional magnetic resonance imaging (fMRI), computed tomography (CT), positron emission tomography (PET), electroencephalography (EEG), magnetoencephalography (MEG), and others. Positron emission tomography (PET) is a type of imaging technique that measures the metabolic activity of the cells of body tissues using radioactive substances. The various applications of brain and neuroimaging devices are Parkinson's disease, traumatic brain injury, epilepsy, dementia, sleep disorders, and other applications that are used in hospitals, diagnostic centers, and ambulatory surgical centers. The brain and neuroimaging devices market research report is one of a series of new reports from The Business Research Company that provides brain and neuroimaging devices market statistics, including brain and neuroimaging devices industry global market size, regional shares, competitors with a brain and neuroimaging devices market share, detailed brain and neuroimaging devices market segments, market trends and opportunities, and any further data you may need to thrive in the brain and neuroimaging devices industry. This brain and neuroimaging devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global brain and neuroimaging devices market size will grow from $35.49 billion in 2022 to $37.53 billion in 2023 at a compound annual growth rate (CAGR) of 5.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The brain and neuroimaging devices market size is expected to grow from $47.15 billion in 2027 at a CAGR of 5.9%. An increase in the incidence of neurological disorders is expected to drive the market. According to a report by the European Academy of Neurology, 1 in 3 people in 2022 are affected by a neurological disease and the number of deaths due to neurological disorders increased by almost 40% in the last 30 years. Brain and neuroimaging devices are used to diagnose neurological disorders increasing the survival rate and management of the disease. This increasing incidence rate is expected to drive the brain and neuroimaging devices market. The high cost of imaging devices is anticipated to hamper the market for brain and neuroimaging devices. Neurological and cognitive psychology research and design brain-computer interfaces require high-end machines such as Electroencephalography (EEG), Positron Emission Tomography (PET), Functional Magnetic Resonance Imaging (fMRI) among others. These are high-cost devices, for instance, the new 64-slice CT scanners range between $500,000 and $700,000, cost of a PETCT scanner ranges from $225,000 to $750,000, which is not affordable for all hospitals and labs, mainly in developing countries. Thus, the high cost of imaging devices hampers the buying capacity of hospitals and diagnostic labs, hampering the brain and neuroimaging devices market. Companies and researchers are focusing on developing portable brain scanners that are expected to revolutionize brain imaging by lowering the cost of devices, making them affordable and accessible to all. EMVision Medical Devices and researchers at Queensland University have developed a portable brain scanner technology that enables brain scanning to be performed at almost any location. Researchers at University College London have developed a portable MEG brain scanner that is lightweight, worn like just a helmet but can measure brain activity even as people make natural movements, providing improved imaging opportunities for patients with disorders that cause unprompted body movements, such as epilepsy. Major players in the brain and neuroimaging devices market are GE, Siemens, Philips, Canon, Hitachi Medical Systems, Medtronic PLC., EB Neuro S.p.A., Neurosoft, MinFound Medical Systems Co. Ltd., and Elekta. Western Europe was the largest region in the brain and neuroimaging devices market in 2022. North America was the second largest region in the global brain and neuroimaging devices market report. Africa. was the smallest region in the brain and neuroimaging devices market. The regions covered in the global brain and neuroimaging devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the brain and neuroimaging devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The brain and neuroimaging devices market consists of sales of imaging equipment for brain and nerves such as functional magnetic resonance imaging, computed tomography, positron emission tomography (pet), electroencephalography, magnetoencephalography, and others. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values – that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced. It does not include revenues from resales along the supply chain or as part of other products. The global brain and neuroimaging devices market is segmented - 1) By Imaging Type: Functional Magnetic Resonance Imaging (fMRI), Computed Tomography (CT), Positron Emission Tomography (PET), Electroencephalography (EEG), Magneto Encephalography (MEG), Other Imaging Types 2) By End-user: Hospitals, Diagnostic Centres, Ambulatory Surgical Centres 3) By Application: Parkinson’s Disease, Traumatic Brain Injury, Epilepsy, Dementia, Sleep Disorders, Other Applications

Neuroprosthetics is the study of neuroprostheses and brain-machine interfaces. Neuroprosthetic devices substitute the cognitive or sensory functions that have been impaired due to nervous system disorders. They encompass various artificial devices or systems that can enhance the output or input of a neural system. The major purpose of neuroprosthetics is to allow brain-injured patients to participate in day-to-day life and improve their quality of life. The main types of neuroprosthetics are motor neuroprosthetics, auditory neuroprosthetics/ cochlear implants, visual neuroprosthetics/ retinal implants, and cognitive neuroprosthetics. As an orthosis, motor neuroprosthesis (MN) includes electrical stimulation of brain areas to promote the activities and involvement of persons who have had a stroke in their natural environment. The various techniques used are spinal cord stimulation, deep brain stimulation, vagus nerve stimulation, sacral nerve stimulation, and transcranial magnetic stimulation which are applied in various disorders such as motor neuron disorders, physiological disorders, and cognitive disorders. The neuroprosthetics market research report is one of a series of new reports from The Business Research Company that provides neuroprosthetics market statistics, including neuroprosthetics industry global market size, regional shares, competitors with a neuroprosthetics market share, detailed neuroprosthetics market segments, market trends and opportunities, and any further data you may need to thrive in the neuroprosthetics industry. This neuroprosthetics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global neuroprosthetics market size grew from $8.09 billion in 2022 to $9.24 billion in 2023 at a compound annual growth rate (CAGR) of 14.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The neuroprosthetics market size is expected to grow to $16.03 billion in 2027 at a CAGR of 14.7%. The rising patient population suffering from neurological disorders and nerve injuries is expected to propel the growth of the neuroprosthetics market. Neurological disorders are referred to as disorders that affect the brain and the nerves present in the human body and the spinal cord. Nerve injuries are the damages caused to nerves due to pressure, cuts, or stretching during an accident or any unpredicted event. Neuroprosthetics help patients with such disorders and injuries to restore their lost motor and sensory functions. For instance, according to the world Health Oganization (WHO), a Switzerland-based health agency of the united nations, in 2022, 50 million people globally were suffering from epilepsy, nearly 80% of them were living in low and middle-income countries. Therefore, the growing patient population suffering from neurological disorders and nerve injuries is driving the growth of the neuroprosthetics market. Technological advancements are shaping the neuroprosthetics market. Technological advancement is defined as a discovery of knowledge that advances technology to provide an enhanced product to the customers. For instance, in July 2021, the University of California San Francisco Parnassus Campus (UCSF), a US-based academic medical center, developed Speech Neuroprosthesis. The new achievement was developed by researchers of UCSF, which enabled paralysis patients to directly translate the signals from their brain to the vocal tract, which appear as text on the screen. The technology used is Brain-Computer Interface Restoration of Arm and Voice which uses human vocabulary with advanced computer algorithms that are used to recognize brain activity. In February 2021, Flow Neuroscience, a Sweden-based developer of a brain stimulation device, acquired Halo Neuroscience, for an undisclosed amount. With this acquisition, Flow Neuroscience aims at providing more personalized solutions related to brain disorders. Halo Neuroscience is a US-based developer of brain stimulators that develops muscle memory faster and develops and designs neuroprosthetics. Major players in the neuroprosthetics market are Medtronic plc, Cochlear Ltd., Abbott Laboratories, Boston Scientific, LivaNova PLC., Second Sight Medical Products Inc., MED-EL, Retina Implant AG, Sonova, Neuropace, NDI Medical LLC, Demant AS, Oticon, St. Jude Medical Inc. and Biomet Inc. North America was the largest region in the neuroprosthetics market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in neuroprosthetics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the neuroprosthetics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The neuroprosthetics market includes revenues earned by entities by peripheral nerve, brain-computer interface, electro stimulation, neurostimulation, cochlear implant, stimulation, femoral nerve and carbon nanotube. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global neuroprosthetics market is segmented - 1) By Type: Motor Neuroprosthetics, Auditory Neuroprosthetics/ Cochlear implants, Visual Neuroprosthetics/ Retinal implants, Cognitive Neuroprosthetics 2) By Technique: Spinal Cord Stimulation, Deep Brain Stimulation, Vagus Nerve Stimulation, Sacral Nerve Stimulation, Transcranial Magnetic Stimulation 3) By Application: Motor Neuron Disorders, Physiological Disorders, Cognitive Disorders